Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) stock was trading low in the after-hours as they dropped -13.06% to $4.46. Over the past three months, the stock’s price change was -21.08% and -1.91% over the five days. It is currently trading at a low of $53.15 and touched a high of $138.79 in the past 12 months.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
So, what are they good at…?
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Infusion solutions that improve the quality of life for millions of patients worldwide are developed, manufactured, and commercialized by KORU Medical Systems (NASDAQ: KRMD).
Read More
What happened…
On January 25, 2021, the company reported preliminary financial results for the whole fiscal year ended December 31, 2020. Additionally, Jim Beck was named Interim Chief Executive Officer of the Company, effective immediately after serving as a KORU Medical Board member. Don Pettigrew has resigned from his position as President and CEO, and the Board of Directors has engaged a leading executive search firm to assist in hiring a new CEO.
For the full year 2020, preliminary revenue is expected to be $24.0 million, an increase of 3.4% from $23.2 million in 2019.
Preliminary cash, cash equivalents, marketable securities, and other pro forma financial assets are projected to amount to $27.3 million at the end of 2020, compared to $5.9 million at the end of 2019.
Meanwhile, the Company noted several factors that impacted preliminary 2020 results, including the significant demand fluctuations resulting from large-scale inventory purchasing. Growth in net revenue was slower due to strengthening the Company’s purchasing power with large customers. International sales and clinical trial partnerships performed less than expected in the second half of 2020. State and local guidelines prevented many people from seeking care from their healthcare professionals in 2020, resulting in a slowdown in new patient starts.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Conclusively…
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can gather important information from reading the tea leaves about who is buying and selling.65.79% of this stock is owned by institutions, while insiders hold 4.40%. The top institutional shareholder is Horton Capital Management, LLC with 29.66%, followed by First Light Asset Management, LLC with 18.19%.